News
A Clear Signal from Europe's Largest Medical Market
Germany remains the most closely watched medical cannabis market in Europe, not least because of its sheer scale. Since the country moved to descheduled cannabis for adult recreational use in April 2024, its parallel medical framework has continued to generate data that other European regulators — including Malta's Authority on the Responsible Use of Cannabis (ARUC) — would be unwise to ignore. The latest figures, reported by Newsweed, point to a striking pattern: when German patients are given a choice, they consistently opt for cannabis products with higher THC concentrations.
What the German Data Shows
According to reporting based on prescription and dispensing data from the German market, patients accessing medical cannabis through the country's pharmacy system are disproportionately selecting high-THC flower and extracts over CBD-dominant or balanced-ratio products. While specific figures from the underlying dataset were not independently verifiable at time of publication, the directional trend aligns with what clinicians and pharmacists across Germany have been observing anecdotally for some time: patients self-selecting toward higher potency.
This is not, by itself, surprising. THC is the primary psychoactive cannabinoid and the one most commonly associated with symptom relief in conditions including chronic pain, nausea, appetite loss, and certain sleep disorders. Patients who have navigated the often considerable bureaucratic hurdles of accessing medical cannabis in a European country are, typically, motivated users seeking meaningful therapeutic effect — and for many, that means THC.
What makes the German data notable is the context in which it emerges. Germany has, in recent years, progressively liberalised both medical and recreational access. The professional expectation was that broader availability might normalise lower-potency or balanced products. The opposite appears to be occurring, at least within the medical cohort.
Implications for European Regulators
Germany's experience is being watched closely by health ministries and cannabis authorities across the EU. Several member states, including Portugal, the Czech Republic, and Luxembourg, are at varying stages of developing or refining their own frameworks. Each is grappling with similar questions: how to define appropriate potency thresholds, how to structure patient access, and how prescribing guidance should account for individual tolerance and therapeutic goals.
The German data complicates a regulatory instinct that has been present in many European frameworks — including Malta's — to treat high THC content as inherently riskier and therefore something to be restricted or discouraged. Public health logic supports caution around high-potency products, particularly in consumer-facing recreational contexts. But the medical picture is more nuanced. Clinicians argue that for certain patient populations, a higher THC concentration may produce therapeutic outcomes with a lower volume of product consumed, which carries its own harm-reduction rationale.
The Maltese Context
Malta's medical cannabis framework, administered through ARUC, has taken a cautious and measured approach to potency since its inception. The island's Cannabis Harm Reduction Associations (CHRAs) operate under a non-commercial, association-based model that is structurally distinct from the pharmacy-based dispensing system used in Germany. Nonetheless, the question of product potency is equally relevant here.
ARUC has not publicly set fixed THC caps for products accessed through CHRAs, but the licensing and cultivation framework does impose oversight over what member associations can grow and distribute. As Maltese-grown cannabis begins to reach CHRA members in greater volumes, the question of what strains and potency profiles are available — and whether they meet the expectations of the patients and enthusiasts using them — is becoming more pressing.
Conversations within the local cannabis community suggest that, not unlike their German counterparts, Maltese users often express preference for higher-potency products, particularly those managing conditions such as chronic pain or insomnia. Whether ARUC's framework will evolve to accommodate a more evidence-based approach to potency — one informed by data like that emerging from Germany — remains to be seen.
A Policy Conversation Worth Having
No regulatory framework should be designed around consumer preference alone. Harm reduction, clinical guidance, and evidence on dependency risk must all factor into potency policy. But equally, a framework that systematically provides patients with products they find therapeutically inadequate is one that pushes demand toward the unregulated market — the very outcome regulators most want to avoid.
Germany's data does not settle this debate, but it does sharpen it. For Malta, a small jurisdiction with a young and still-evolving cannabis authority, paying close attention to what Europe's largest market is learning in real time is not optional. It is part of responsible policymaking.
Sources:
Newsweed
Featured image: Photo by Terrance Barksdale on Pexels
Members Discussion